ArticleEuropean journal of epidemiology2020
Hospitalization following influenza infection and pandemic vaccination in multiple sclerosis patients: a nationwide population-based registry study from Norway.
Article in European journal of epidemiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: A systematic review.Multiple sclerosis and related disorders · 2021Pooled it
- Multiple Sclerosis and Viruses: « Liaisons Dangereuses ».Reviews in medical virology · 2026Review
- Risk and resilience factors associated with the progression of influenza to severe disease outcomes: umbrella review protocol.BMJ open · 2025Article
- Trauma Burden Affected People with Multiple Sclerosis During SARS-CoV-2 Pandemic.Journal of clinical medicine · 2025Article
- Proteomic analysis reveals dysregulation of peripheral blood neutrophils in patients with Multiple Sclerosis.Clinical and experimental immunology · 2025Article
- Review
- Vaccination frequency in people newly diagnosed with multiple sclerosis.Multiple sclerosis (Houndmills, Basingstoke, England) · 2023Article
- Summary of Safety and Efficacy of COVID Vaccination in Patients with Multiple Sclerosis.European neurology · 2023Review
- Clinical and economic burden of physician-diagnosed influenza in adults during the 2017/2018 epidemic season in Spain.BMC public health · 2022Article
- Quantitative and qualitative features of acute phase-adverse events following SARS-CoV-2 vaccination in a large sample of people with multiple sclerosis.Multiple sclerosis and related disorders · 2022Article
- Uptake and Attitudes About Immunizations in People With Multiple Sclerosis.Neurology. Clinical practice · 2021Article
- Multiple Sclerosis, Disease-Modifying Therapies and COVID-19: A Systematic Review on Immune Response and Vaccination Recommendations.Vaccines · 2021Review
- Current Immunological and Clinical Perspective on Vaccinations in Multiple Sclerosis Patients: Are They Safe after All?International journal of molecular sciences · 2021Review
- Is multiple sclerosis a risk factor for infections?Multiple sclerosis and related disorders · 2020Article
- Objectives, design and main findings until 2020 from the Rotterdam Study.European journal of epidemiology · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Patients with multiple sclerosis (MS) are at increased risk of infections and related worsening of neurological function. Influenza infection has been associated with increased risk of various neurological complications. We conducted a population-based registry study to investigate the risk of acute hospitalization of MS patients in relation to influenza infection or pandemic vaccination in Norway. The entire Norwegian population in the years 2008-2014 was defined as our study population (N = 5,219,296). Information on MS diagnosis, influenza infection and vaccination were provided by Norwegian national registries. The self-controlled case series method was used to estimate incidence rate ratios (IRRs) with 95% confidence intervals (95% CI) in defined risk periods. 6755 MS patients were identified during the study period. Average age at first registration of an MS diagnosis was 51.8 years among men and 49.9 years among females (66.9%). The IRR for emergency hospitalization among MS patients the first week after an influenza diagnosis was 3.4 (95% CI 2.4-4.8). The IRR was 5.6 (95% CI 2.7-11.3) after pandemic influenza, and 4.8 (95% CI 3.1-7.4) after seasonal influenza. Pandemic vaccination did not influence risk of hospitalization [IRR within the first week: 0.7 (95% CI 0.5-1.0)]. Among MS patients, influenza infection was associated with increased risk for acute hospitalization while no increased risk was observed after pandemic vaccination. Influenza vaccination could prevent worsening of MS-related symptoms as well as risk of hospitalization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.